Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I dose escalation trial of neoadjuvant sorafenib and concurrent sorafenib, cisplatin and radiation in locally advanced squamous cell carcinomas of the head and neck (SCCHN)

Next Previous
Search
Trial Profile

A phase I dose escalation trial of neoadjuvant sorafenib and concurrent sorafenib, cisplatin and radiation in locally advanced squamous cell carcinomas of the head and neck (SCCHN)

Status: Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 18 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cisplatin; Sorafenib
  • Indications Head and neck cancer
  • Focus Adverse reactions

    • Most Recent Events

    • 20 Jul 2016 Biomarkers information updated
    • 04 Nov 2010 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 20 Mar 2008 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top